JP2004340957A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004340957A5 JP2004340957A5 JP2004128141A JP2004128141A JP2004340957A5 JP 2004340957 A5 JP2004340957 A5 JP 2004340957A5 JP 2004128141 A JP2004128141 A JP 2004128141A JP 2004128141 A JP2004128141 A JP 2004128141A JP 2004340957 A5 JP2004340957 A5 JP 2004340957A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- protein
- seq
- bladder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 62
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 36
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 36
- 150000003839 salts Chemical class 0.000 claims 25
- 102000040430 polynucleotide Human genes 0.000 claims 22
- 108091033319 polynucleotide Proteins 0.000 claims 22
- 239000002157 polynucleotide Substances 0.000 claims 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 19
- 208000035475 disorder Diseases 0.000 claims 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 14
- 230000027939 micturition Effects 0.000 claims 14
- 230000003247 decreasing effect Effects 0.000 claims 13
- 102000005962 receptors Human genes 0.000 claims 11
- 108020003175 receptors Proteins 0.000 claims 11
- 238000012216 screening Methods 0.000 claims 11
- 230000027455 binding Effects 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 9
- 230000008447 perception Effects 0.000 claims 9
- 230000005540 biological transmission Effects 0.000 claims 8
- 239000003446 ligand Substances 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- 206010003210 Arteriosclerosis Diseases 0.000 claims 7
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 7
- 206010016654 Fibrosis Diseases 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 7
- 208000006011 Stroke Diseases 0.000 claims 7
- 208000025371 Taste disease Diseases 0.000 claims 7
- 206010052428 Wound Diseases 0.000 claims 7
- 208000027418 Wounds and injury Diseases 0.000 claims 7
- 238000009825 accumulation Methods 0.000 claims 7
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 235000012000 cholesterol Nutrition 0.000 claims 7
- 230000007882 cirrhosis Effects 0.000 claims 7
- 208000019425 cirrhosis of liver Diseases 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- 206010012601 diabetes mellitus Diseases 0.000 claims 7
- 230000001079 digestive effect Effects 0.000 claims 7
- 208000019622 heart disease Diseases 0.000 claims 7
- 208000003532 hypothyroidism Diseases 0.000 claims 7
- 230000002989 hypothyroidism Effects 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 208000010125 myocardial infarction Diseases 0.000 claims 7
- 230000000069 prophylactic effect Effects 0.000 claims 7
- 235000019669 taste disorders Nutrition 0.000 claims 7
- 210000001835 viscera Anatomy 0.000 claims 7
- 206010005052 Bladder irritation Diseases 0.000 claims 6
- 208000020446 Cardiac disease Diseases 0.000 claims 6
- 206010020853 Hypertonic bladder Diseases 0.000 claims 6
- 206010020880 Hypertrophy Diseases 0.000 claims 6
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 6
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 claims 6
- 208000009911 Urinary Calculi Diseases 0.000 claims 6
- 206010046543 Urinary incontinence Diseases 0.000 claims 6
- 201000003146 cystitis Diseases 0.000 claims 6
- 206010029446 nocturia Diseases 0.000 claims 6
- 208000020629 overactive bladder Diseases 0.000 claims 6
- 210000002307 prostate Anatomy 0.000 claims 6
- 201000004240 prostatic hypertrophy Diseases 0.000 claims 6
- 230000008085 renal dysfunction Effects 0.000 claims 6
- 208000023504 respiratory system disease Diseases 0.000 claims 6
- 201000005572 sensory peripheral neuropathy Diseases 0.000 claims 6
- 208000009935 visceral pain Diseases 0.000 claims 6
- 206010007027 Calculus urinary Diseases 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 5
- 230000005980 lung dysfunction Effects 0.000 claims 5
- 108091006027 G proteins Proteins 0.000 claims 4
- 102000030782 GTP binding Human genes 0.000 claims 4
- 108091000058 GTP-Binding Proteins 0.000 claims 4
- 206010029279 Neurogenic bladder Diseases 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 230000007423 decrease Effects 0.000 claims 4
- 239000000032 diagnostic agent Substances 0.000 claims 4
- 229940039227 diagnostic agent Drugs 0.000 claims 4
- 239000002184 metal Substances 0.000 claims 4
- 230000036299 sexual function Effects 0.000 claims 4
- 201000001880 Sexual dysfunction Diseases 0.000 claims 3
- 231100000872 sexual dysfunction Toxicity 0.000 claims 3
- 230000001568 sexual effect Effects 0.000 claims 3
- 206010036018 Pollakiuria Diseases 0.000 claims 2
- 208000004168 Underactive Urinary Bladder Diseases 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000035807 sensation Effects 0.000 claims 2
- 235000019615 sensations Nutrition 0.000 claims 2
- 230000019491 signal transduction Effects 0.000 claims 2
- 208000022934 urinary frequency Diseases 0.000 claims 2
- 230000036318 urination frequency Effects 0.000 claims 2
- 206010033799 Paralysis Diseases 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000001965 increasing effect Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 208000008281 urolithiasis Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004128141A JP4542810B2 (ja) | 2003-04-25 | 2004-04-23 | 新規スクリーニング方法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003122464 | 2003-04-25 | ||
| JP2004128141A JP4542810B2 (ja) | 2003-04-25 | 2004-04-23 | 新規スクリーニング方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004340957A JP2004340957A (ja) | 2004-12-02 |
| JP2004340957A5 true JP2004340957A5 (enExample) | 2007-06-14 |
| JP4542810B2 JP4542810B2 (ja) | 2010-09-15 |
Family
ID=33543298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004128141A Expired - Fee Related JP4542810B2 (ja) | 2003-04-25 | 2004-04-23 | 新規スクリーニング方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4542810B2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7781175B2 (en) * | 2004-04-23 | 2010-08-24 | Takeda Pharmaceutical Company Limited | Method of screening compounds which alter the binding properties of GPR39, and homologs thereof, to bile acid |
| JP2006169165A (ja) * | 2004-12-15 | 2006-06-29 | Itoham Foods Inc | マイクロチップ積層型化学反応装置を使用したペプチド合成方法 |
| JP2009512454A (ja) * | 2005-10-20 | 2009-03-26 | ビアメト ファーマシューティカルズ，インク． | 金属タンパク質のメタル化経路のモジュレーターのスクリーニング方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6720146B2 (en) * | 1999-09-10 | 2004-04-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
| JP2003024070A (ja) * | 2001-06-05 | 2003-01-28 | Pharma Design Inc | 新規なｇタンパク質共役型受容体タンパク質及びその遺伝子 |
| JP2003047472A (ja) * | 2001-08-01 | 2003-02-18 | Takeda Chem Ind Ltd | 新規ｇタンパク質共役型レセプタータンパク質およびそのｄｎａ |
-
2004
- 2004-04-23 JP JP2004128141A patent/JP4542810B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8883721B2 (en) | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof | |
| JP5645339B2 (ja) | 摂食行動の修正 | |
| JP6124986B2 (ja) | 拡張期心不全を処置するための増殖分化因子（ｇｄｆ） | |
| TW200510349A (en) | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | |
| JP2014208675A (ja) | 満腹ホルモン放出の刺激 | |
| HU208088B (en) | Process for producing composition suitable for inducing erection | |
| JP2004524340A (ja) | 非ニューロパシー炎症性疼痛を治療するための化合物のペプチドクラスの新規の使用 | |
| Davenport et al. | Treating obesity: is it all in the gut? | |
| Yagi et al. | Intramedullary spinal cord tumour associated with neurofibromatosis type 1 | |
| ATE330588T1 (de) | Verwendung von bradycardica bei der behandlung von mit hypertrophie einhergehenden myocarderkrankungen und neue arzneimittelkombinationen | |
| JP2004340957A5 (enExample) | ||
| WO1998007445A1 (en) | Preventive/remedy for frequent urination and urinary incontinence | |
| US11219668B2 (en) | Method of treating a vasculopathy in a human subject | |
| US6376513B1 (en) | Drug for relieving pain and promoting the removal of calculi in urolithiasis | |
| JP2005523270A5 (enExample) | ||
| US20150368220A1 (en) | Pharmaceutical composition for treating or preventing stress urinary incontinence or mixed urinary incontinence, and method for screening compound comprised in said pharmaceutical composition | |
| Onaga et al. | Pituitary adenylate cyclase-activating polypeptide (PACAP) induces duodenal phasic contractions via the vagal cholinergic nerves in sheep | |
| WO2023182342A1 (ja) | 骨格筋増強剤 | |
| Nakada et al. | In vitro contractile effects of neurokinin receptor blockade in the human ureter | |
| JP2004073182A5 (enExample) | ||
| Azriel et al. | Characterization and autoradiographic localization of neurotensin binding sites in human sigmoid colon | |
| WO2011019399A1 (en) | Preservation of blood vessels using phosphodiesterase inhibitors | |
| Jerde et al. | NK‐2 is the predominant tachykinin receptor subtype in the swine ureter | |
| EP2344176A1 (en) | Use of bradykinin b1 receptor antagonists in intestinal fibrosis treatment | |
| Lefebvre et al. | Influence of the selective neuronal NO synthase inhibitor ARL 17477 on nitrergic neurotransmission in porcine stomach |